Switching At Low HIV-1RNA Into Fixed dose combinations


SALIF is a multi-site study in suppressed HIV-1 infected patients who are on 1st line Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-based Highly Active Anti-Retroviral Therapy (HAART) with undetectable viral load. Patients will be switched (ratio 1:1) to rilpivirine/tenofovir/emtricitabine (RPV/TDF/FTC) or efavirenz/tenofovir/lamivudine (EFV/TDF/3TC).


Thailand has many years of experience with combination ART to treat HIV infected individuals. SALIF is welcomed in Thailand as an important study, as highlighted by Assoc. Prof. Winai Ratanasuwan from Siriraj Hospital:

“One thing I know is that fixed dose combinations (FDC) will help to reduce resistance and increase adherence. Even though we know a lot about HIV treatment, yet there are still many unanswered questions, and some patients continue to have problems with adherence, and sexual transmitted infections, drug resistance and effects that alter the basic blood profile such as increased in triglycerides and cholesterol.”


Name: SALIF: Switching At Low HIV-1RNA Into Fixed dose combinations
Status: Active
Principal Investigators: Dr Weerawat Manosuthi

Dr. Anchalee Avihingsanon

Dr Winai Rattanasuwan

Prof. Khuanchai Supparatpinyo

Departments(s): Leiden University Medical Center
Partners: AIGHD Asia, with their local partners:


Siriraj Hospital

Bamrasnaradura Infectious Diseases Institute

Maharaj Nakorn Chiang Mai Hospital

Contact information: Project Manager: Jolien van der Vaart


Duration: Start date: 8 August 2013

Duration: 32 months

End date: 1 April 2016

Funded by: Johnson and Johnson
Countries: Thailand